Table 5.

Sperm-inducing treatment information for 10 male congenital hypogonadotropic hypogonadism patients carrying mutations in fibroblast growth factor receptor 1 (FGFR1)

Patient	Inheritance	TRT	TRT time (month)	ST	Before spermatogenesis therapy					Age (year)	Time required for spermatogenesis (month)	Last visit during spermatogenesis therapy
					LH (IU l−1)	FSH (IU l−1)	Testosterone (ng ml−1)	TV (ml)	Sperm concentration (×106 ml−1)			LH (IU l−1)	FSH (IU l−1)	Testosterone (ng ml−1)	TV (ml)	Sperm concentration (×106 ml−1)
Male 1	+	+	24	hCG/HMG	0.20	1.10	3.46	2.0	−	24	36	0.65	2.36	1.7	5	2.00
Male 2	+	+	17	hCG/HMG	0.90	2.20	1.28	3.0	−	18	32	0.78	2.85	7.0	6	7.79
Male 3	+	+	16	GnRH	0.20	0.32	0.49	2.0	−	29	11	8.45	13.66	3.9	3	9.92
Male 4	+	+	36	GnRH	0.60	1.30	5.90	3.0	−	17	5	13.00	8.00	7.4	15	10.73
Male 5	+	+	24	GnRH	0.76	1.80	2.00	3.0	−	26	10	3.14	3.81	2.1	6	4.00
Male 6	+	+	48	GnRH	0.20	0.26	4.42	5.0	−	17	−	11.06	8.63	3.7	5	0
Male 7	−	+	24	GnRH	0.20	0.30	1.30	4.0	−	19	9	4.85	11.92	2.1	5	2.00
Male 8	−	+	65	GnRH	0.20	0.20	3.14	1.0	−	27	10	9.52	26.42	3.3	6	7.97
Male 9	−	+	36	hCG/HMG	0.20	0.20	3.80	2.0	−	20	−	0.84	2.25	2.2	7	0
Male 10	−	+	5	GnRH	0.20	0.30	0.90	0.5	−	17	−	5.78	2.68	1.7	8	0

In inheritance column, +: mutations derived from parents; −: de novo mutants. In sperm concentration column, −: none. In time required for spermatogenesis column, −: none. TRT: testosterone replacement therapy; ST: spermatogenesis therapy; hCG/HMG: human chorionic gonadotropin and human menopausal gonadotropin; GnRH: gonadotropin-releasing hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; TV: testis volume